The company will continue selling the products, but Purdue's sales force "will no longer be visiting offices to engage in discussions about opioid products", the company said, confirming an earlier report by Bloomberg.
"We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers", the company said in a statement. Instead, any questions doctors have will be directed to the Stamford, Conn. -based company's medical affairs department.
About 200 remaining Purdue salespeople will focus on promoting the company's drug to treat opioid-induced constipation, Symproic.
Opioids were involved in more than 42,000 overdose deaths in 2016, according to the U.S. Centers for Disease Control and Prevention. OxyContin is the nation's top-selling opioid painkiller.
Alabama last Tuesday became the latest state to file a lawsuit accusing the private CT company of fueling the US epidemic by misrepresenting the risks and benefits of opioids. Alabama Attorney General Steve Marshall filed a lawsuit on Tuesday accusing Purdue of deceptively marketing prescription opioids.
Purdue is also facing a federal investigation by the U.S. Attorney's Office in CT.
Purdue Pharma denies allegations of complicity in the opioid epidemic and says it is committed to curbing rates of opioid abuse. It has said its drugs are approved by the U.S. Food and Drug Administration and account for only 2 percent of all opioid prescriptions. The company in 2007 paid out $600 million to settle civil and criminal charges related to the drug's marketing, with three company executives agreeing to pay an additional $34.5 million.
That year, Purdue also reached a $19.5-million settlement with 26 states and the District of Columbia. He has yet to declare it a national emergency as he pledged to do in August following a recommendation by a presidential commission.